SAGE-718
Cognitive Impairment - Huntington's Disease
Key Facts
About Sage Therapeutics
Sage Therapeutics' mission is to pioneer life-changing brain health medicines, achieving a landmark success with the first FDA-approved drug for postpartum depression, ZULRESSO. The company's strategy is built on a proprietary platform targeting GABA and NMDA receptors to develop rapid-onset therapies for mood and neurological disorders. While facing commercial challenges, Sage is advancing a promising pipeline and has implemented strategic partnerships and cost reductions to extend its runway and focus on high-value programs.
View full company profileAbout Sage Therapeutics
Sage Therapeutics' mission is to pioneer life-changing brain health medicines, achieving a landmark success with the first FDA-approved drug for postpartum depression, ZULRESSO. The company's strategy is built on a proprietary platform targeting GABA and NMDA receptors to develop rapid-onset therapies for mood and neurological disorders. While facing commercial challenges, Sage is advancing a promising pipeline and has implemented strategic partnerships and cost reductions to extend its runway and focus on high-value programs.
View full company profileAbout Sage Therapeutics
Sage Therapeutics' mission is to pioneer life-changing brain health medicines, achieving a landmark success with the first FDA-approved drug for postpartum depression, ZULRESSO. The company's strategy is built on a proprietary platform targeting GABA and NMDA receptors to develop rapid-onset therapies for mood and neurological disorders. While facing commercial challenges, Sage is advancing a promising pipeline and has implemented strategic partnerships and cost reductions to extend its runway and focus on high-value programs.
View full company profile